Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$806.46
-1.2%
$767.17
$510.05
$934.62
$50.51B0.46347,730 shs171,192 shs
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$85.93
+3.3%
$81.42
$72.30
$87.89
$47.91B0.875.09 million shs4.94 million shs
Icon Plc stock logo
ICLR
Icon
$116.78
+0.2%
$110.44
$66.57
$211.00
$9.41B1.231.28 million shs383,734 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+1.49%-0.72%+1.35%-3.34%+39.54%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
+0.47%+2.43%+4.31%+4.20%+9.32%
Icon Plc stock logo
ICLR
Icon
+1.29%-0.44%+1.21%+16.92%-7.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
argenex SE stock logo
ARGX
argenex
$806.46
-1.2%
$767.17
$510.05
$934.62
$50.51B0.46347,730 shs171,192 shs
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$85.93
+3.3%
$81.42
$72.30
$87.89
$47.91B0.875.09 million shs4.94 million shs
Icon Plc stock logo
ICLR
Icon
$116.78
+0.2%
$110.44
$66.57
$211.00
$9.41B1.231.28 million shs383,734 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
argenex SE stock logo
ARGX
argenex
+1.49%-0.72%+1.35%-3.34%+39.54%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
+0.47%+2.43%+4.31%+4.20%+9.32%
Icon Plc stock logo
ICLR
Icon
+1.29%-0.44%+1.21%+16.92%-7.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
argenex SE stock logo
ARGX
argenex
2.92
Moderate Buy$1,017.7826.20% Upside
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
2.79
Moderate Buy$95.6511.31% Upside
Icon Plc stock logo
ICLR
Icon
2.24
Hold$145.6724.74% Upside

Current Analyst Ratings Breakdown

Latest ARGX, EW, and ICLR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/18/2026
Icon Plc stock logo
ICLR
Icon
Lower Price TargetNeutral$175.00 ➝ $120.00
5/18/2026
Icon Plc stock logo
ICLR
Icon
Initiated CoverageSector Perform$123.00
5/8/2026
argenex SE stock logo
ARGX
argenex
Boost Price TargetBuy$1,120.00 ➝ $1,135.00
5/8/2026
argenex SE stock logo
ARGX
argenex
Boost Price TargetOverweight$1,247.00 ➝ $1,260.00
5/4/2026
Icon Plc stock logo
ICLR
Icon
Set Price Target$125.00
4/27/2026
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Reiterated RatingOverweight$104.00 ➝ $110.00
4/24/2026
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Set Price TargetHold$89.00 ➝ $90.00
4/24/2026
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Reiterated RatingOutperform$93.00
4/24/2026
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Set Price TargetHold$87.00 ➝ $85.00
4/24/2026
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Boost Price TargetNeutral$85.00 ➝ $87.00
4/24/2026
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
Boost Price TargetBuy$98.00 ➝ $100.00
(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
argenex SE stock logo
ARGX
argenex
$4.25B11.75$21.08 per share38.26$118.34 per share6.81
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$6.07B8.15$2.94 per share29.18$17.94 per share4.79
Icon Plc stock logo
ICLR
Icon
$8.28B1.14$20.07 per share5.82$117.92 per share0.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
argenex SE stock logo
ARGX
argenex
$1.29B$22.4635.9124.781.2931.31%33.28%28.16%7/23/2026 (Estimated)
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$1.07B$1.8845.7125.652.0917.39%15.19%11.71%7/23/2026 (Estimated)
Icon Plc stock logo
ICLR
Icon
$791.47M$7.3915.808.923.047.40%10.58%6.01%5/27/2026 (Estimated)

Latest ARGX, EW, and ICLR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/27/2026Q1 2026
Icon Plc stock logo
ICLR
Icon
$2.95$3.28+$0.33N/A$1.99 billion$2.00 billion
5/7/2026Q1 2026
argenex SE stock logo
ARGX
argenex
$5.74$5.52-$0.22$5.52$1.44 billion$1.31 billion
4/23/2026Q1 2026
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
$0.7280$0.78+$0.0520$0.66$1.60 billion$1.65 billion
3/31/2026Q1 2026
argenex SE stock logo
ARGX
argenex
N/A$5.52N/A$5.52N/A$1.31 billion
2/26/2026Q4 2025
argenex SE stock logo
ARGX
argenex
$6.05$8.02+$1.97$8.02$1.30 billion$1.32 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
argenex SE stock logo
ARGX
argenex
N/AN/AN/AN/AN/A
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
argenex SE stock logo
ARGX
argenex
N/A
5.23
4.87
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.06
4.42
3.63
Icon Plc stock logo
ICLR
Icon
0.31
1.06
1.06

Institutional Ownership

CompanyInstitutional Ownership
argenex SE stock logo
ARGX
argenex
60.32%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
79.46%
Icon Plc stock logo
ICLR
Icon
95.61%

Insider Ownership

CompanyInsider Ownership
argenex SE stock logo
ARGX
argenex
2.43%
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
0.31%
Icon Plc stock logo
ICLR
Icon
44.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
argenex SE stock logo
ARGX
argenex
1,86361.88 million60.38 millionOptionable
Edwards Lifesciences Corporation stock logo
EW
Edwards Lifesciences
16,000575.80 million574.02 millionOptionable
Icon Plc stock logo
ICLR
Icon
41,90080.76 million45.22 millionOptionable

Recent News About These Companies

Icon (NASDAQ:ICLR) Shares Gap Up - What's Next?
Is Icon Public Limited Company (ICLR) Undervalued?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
argenex stock logo

argenex NASDAQ:ARGX

$806.46 -9.76 (-1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$807.39 +0.93 (+0.12%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Edwards Lifesciences stock logo

Edwards Lifesciences NYSE:EW

$85.93 +2.73 (+3.28%)
Closing price 03:59 PM Eastern
Extended Trading
$85.21 -0.72 (-0.84%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Icon stock logo

Icon NASDAQ:ICLR

$116.78 +0.21 (+0.18%)
Closing price 04:00 PM Eastern
Extended Trading
$115.47 -1.31 (-1.12%)
As of 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.